PharmaCorp Rx (TSXV:PCRX) Short-Term Debt: C$0.39 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PCRX PharmaCorp Rx Inc TSXV:PCRX
35 GF Score
Price C$0.49
! 2 Warning Signs
View Full Analysis

What is PharmaCorp Rx Short-Term Debt?

PharmaCorp Rx TSXV:PCRX -2.00% 35 Short-Term Debt is C$0.39 Mil as of Mar. 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

PharmaCorp Rx's Short-Term Debt for the quarter that ended in Mar. 2026 was C$0.39 Mil.

PharmaCorp Rx's quarterly Short-Term Debt declined from Sep. 2025 (C$0.41 Mil) to Dec. 2025 (C$0.39 Mil) but then stayed the same from Dec. 2025 (C$0.39 Mil) to Mar. 2026 (C$0.39 Mil).

PharmaCorp Rx's annual Short-Term Debt increased from Dec. 2023 (C$0.00 Mil) to Dec. 2024 (C$0.08 Mil) and increased from Dec. 2024 (C$0.08 Mil) to Dec. 2025 (C$0.39 Mil).

PharmaCorp Rx Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

PharmaCorp Rx Short-Term Debt Related Terms

PharmaCorp Rx Short-Term Debt Historical Data

* Premium members only.

The historical data trend for PharmaCorp Rx's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCorp Rx Short-Term Debt Chart

PharmaCorp Rx Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
0.00 0.00 0.00 0.08 0.39

PharmaCorp Rx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.41 0.39 0.39
TSXV:PCRX
35GF Score
PharmaCorp Rx Inc TSXV:PCRX
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of C$0.39 Mil mean?
PharmaCorp Rx (TSXV:PCRX) has a Short-Term Debt of C$0.39 Mil as of Mar. 2026.
Is PharmaCorp Rx's Short-Term Debt too high?
PharmaCorp Rx's current Short-Term Debt is C$0.39 Mil. Overall, PharmaCorp Rx has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's Short-Term Debt compare to competitors?
PharmaCorp Rx's Short-Term Debt of C$0.39 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Healthcare Providers & Services company?
A good Short-Term Debt depends on the Healthcare Providers & Services industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. PharmaCorp Rx's current Short-Term Debt is C$0.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current Short-Term Debt of C$0.39 Mil. The current Short-Term Debt is C$0.39 Mil. PharmaCorp Rx's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current Short-Term Debt is C$0.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCorp Rx Business Description

Address 303 Wellman Lane, Suite 203, Saskatoon, SK, CAN, S7T 0J1
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
35GF Score

Get the complete analysis for TSXV:PCRX

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.49
Price